BACKGROUND:Estradiol (E(2)) stimulates GH and prolactin secretion and suppresses FSH secretion in postmenopausal women. Whether central nervous system (CNS) or pituitary mechanisms (or both) mediate such actions is not known. OBJECTIVE: Our objective was to distinguish between hypothalamic and pituitary or peripheral (hepatic) actions of E2. SETTING: This study was performed in an academic medical center. DESIGN: This was a double-blind, prospectively randomized, placebo (Pl)-controlled study. METHODS: The capability of a selective, noncompetitive, non-CNS permeant estrogen receptor (ER)-alpha antagonist, fulvestrant (FUL) to antagonize the effects of transdermal E2 and Pl on GH, prolactin, and FSH secretion was assessed in 43 women (ages 50-80 yr) in a four parallel-cohort study. Each woman received four secretagogue infusions to stimulate GH secretion. IGF-I and its binding proteins were measured secondarily. RESULTS: Administration of Pl/E2 increased GH and prolactin concentrations by 100%, and suppressed FSH concentrations by more than 50% (each P<or=0.004 compared with Pl/Pl). Treatment with FUL/E2 compared with Pl/E2 partially relieved estrogen's inhibition of FSH secretion (P=0.041), without altering E2's stimulation of prolactin secretion. ANOVA further revealed that: 1) estrogen milieu (P=0.014) and secretagogue type (P<0.001) each determined GH concentrations; 2) FUL/Pl suppressed IGF-I concentrations (P<0.001); 3) FUL abrogated estrogen's elevation of IGF binding protein-1 concentrations (P<0.001); and 4) FUL did not oppose estrogen's suppression of IGF binding protein-3 concentrations (P<0.001). SUMMARY AND CONCLUSIONS: Responses to a non-CNS permeant ERalpha antagonist indicate that E2 inhibits FSH secretion in part via pituitary/peripheral ERalpha, drives prolactin output via nonpituitary/nonperipheral-ERalpha effects, and directs GH secretion and IGF-I-binding proteins by complex mechanisms.
RCT Entities:
BACKGROUND:Estradiol (E(2)) stimulates GH and prolactin secretion and suppresses FSH secretion in postmenopausal women. Whether central nervous system (CNS) or pituitary mechanisms (or both) mediate such actions is not known. OBJECTIVE: Our objective was to distinguish between hypothalamic and pituitary or peripheral (hepatic) actions of E2. SETTING: This study was performed in an academic medical center. DESIGN: This was a double-blind, prospectively randomized, placebo (Pl)-controlled study. METHODS: The capability of a selective, noncompetitive, non-CNS permeant estrogen receptor (ER)-alpha antagonist, fulvestrant (FUL) to antagonize the effects of transdermal E2 and Pl on GH, prolactin, and FSH secretion was assessed in 43 women (ages 50-80 yr) in a four parallel-cohort study. Each woman received four secretagogue infusions to stimulate GH secretion. IGF-I and its binding proteins were measured secondarily. RESULTS: Administration of Pl/E2 increased GH and prolactin concentrations by 100%, and suppressed FSH concentrations by more than 50% (each P<or=0.004 compared with Pl/Pl). Treatment with FUL/E2 compared with Pl/E2 partially relieved estrogen's inhibition of FSH secretion (P=0.041), without altering E2's stimulation of prolactin secretion. ANOVA further revealed that: 1) estrogen milieu (P=0.014) and secretagogue type (P<0.001) each determined GH concentrations; 2) FUL/Pl suppressed IGF-I concentrations (P<0.001); 3) FUL abrogated estrogen's elevation of IGF binding protein-1 concentrations (P<0.001); and 4) FUL did not oppose estrogen's suppression of IGF binding protein-3 concentrations (P<0.001). SUMMARY AND CONCLUSIONS: Responses to a non-CNS permeant ERalpha antagonist indicate that E2 inhibits FSH secretion in part via pituitary/peripheral ERalpha, drives prolactin output via nonpituitary/nonperipheral-ERalpha effects, and directs GH secretion and IGF-I-binding proteins by complex mechanisms.
Authors: O Vidal; M Lindberg; L Sävendahl; D B Lubahn; E M Ritzen; J A Gustafsson; C Ohlsson Journal: Biochem Biophys Res Commun Date: 1999-11-19 Impact factor: 3.575
Authors: Ming Yan; Margaret E E Jones; Maria Hernandez; Dongling Liu; Evan R Simpson; Chen Chen Journal: Endocrinology Date: 2003-10-16 Impact factor: 4.736
Authors: Catalina Norman; Nanette L Rollene; Dana Erickson; John M Miles; Cyril Y Bowers; Johannes D Veldhuis Journal: Eur J Endocrinol Date: 2013-11-29 Impact factor: 6.664
Authors: Johannes D Veldhuis; Kristi L Mielke; Mihaela Cosma; Cacia Soares-Welch; Remberto Paulo; John M Miles; Cyril Y Bowers Journal: J Clin Endocrinol Metab Date: 2008-12-16 Impact factor: 5.958
Authors: Johannes D Veldhuis; Daniel M Keenan; Joy N Bailey; John M Miles; Cyril Y Bowers Journal: Eur J Endocrinol Date: 2009-05-20 Impact factor: 6.664
Authors: Anissa Lambertino; Victoria Persky; Sally Freels; Henry Anderson; Terry Unterman; Saria Awadalla; Mary Turyk Journal: Chemosphere Date: 2020-09-11 Impact factor: 7.086